Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Inclusion Criteria: * Patients must have newly diagnosed previously untreated AML or relapsed/refractory primary (ie, de novo) or secondary (progression of MDS or myeloproliferative neoplasms \[MPN\], or therapy-related) AML according to the WHO classification with ≥ 5% leukemic blasts in the bone marrow. * Patients with relapsed/refractory primary (ie, de novo) or secondary (progression of MDS or myeloproliferative neoplasms \[MPN\], or therapy-related) AML may have received prior therapies and there are no limits on number of therapies. * Note: There is a requirement of 7 day washout from prior therapy or 5 half-lives, whichever is shorter. * Patients with newly diagnosed or relapsed/refractory high-risk MDS or MDS/MPN (defined as ≥ 10% bone marrow blasts, or intermediate or high risk by International Prognostic Scoring System \[IPSS\], revised \[R\]-IPSS or dynamic \[D\]-IPSS) may also be eligible after discussion with the PI. * Patient must have documentation of an IDH1 R132 mutation obtained prior to registration. IDH mutational status will be assessed locally. * Patients must be ≥ 18 years of age at the time of signing the informed consent form (ICF). * Patients must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted. * Patient is willing and able to adhere to the study visit schedule and other protocol requirements. * Patient has an Eastern Cooperative Oncology Group (ECOG) performance st…